Safely Regenerating and Propagating Key
Body Cell Types

By combining IMG-1 and its proprietary culture and methods into a scalable and repeatable platform, Imagine Pharma has successfully regenerated and propagated billions of keratinocytes, enterocytes, islets, endothelial and pneumocyte cells. These cells can be used to replenish existing body supplies through transplantation or as the cornerstone for novel topical or oral therapeutics.

ProgramDiscoveryPre-ClinicalPhase 1
Regenerative
Medicine
AIPC
Discovery
Pre-Clinical
Phase 1
T1 Diabetes Autologous Transplant
Discovery
Pre-Clinical
Phase 1
Key
2021-2022
2022-2023

AIPCs: Activated Insulin Producing Cells

The combination of Imagine’s IMG-1 and its proprietary culture and methods have shown the regeneration and propagation of safe insulin producing human islet cells (AIPCs). These islet cells can be safely scaled in the billions in short periods of time.

RESEARCH & DEVELOPMENT ENGINE

Powering New Discovery

The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.

We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.

R & D EngineDiscoveryPre-ClinicalPhase 1
2nd Generation Oral Delivery System
Discovery
Pre-Clinical
Phase 1
Additional Oral Biologics
Discovery
Pre-Clinical
Phase 1
Comprehensive Lung Healing Initiative
Discovery
Pre-Clinical
Phase 1
Comprehensive Bowel Initiative
Discovery
Pre-Clinical
Phase 1
Personalized Blood
Vessel
Discovery
Pre-Clinical
Phase 1